Wright Medical Group N.V. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported net sales of $194,106,000 against $170,503,000 a year ago. Operating loss was $9,134,000 against $18,509,000 a year ago. Loss from continuing operations before income taxes was $32,789,000 against $42,944,000 a year ago. Net loss from continuing operations was $35,829,000 or $0.32 per basic and diluted against $34,122,000 or $0.33 per basic and diluted a year ago. Net loss was $42,525,000 or $0.38 per basic and diluted share against $131,870,000 or $1.26 per basic and diluted share a year ago. Non-GAAP net loss from continuing operations, as adjusted was $15,531,000 against $23,826,000 a year ago. Adjusted non-GAAP loss was $9,650,000 against $16,648,000 a year ago. Adjusted non-GAAP loss per share was $0.09 against $0.16 a year ago. Non-GAAP EBITDA was $7,449,000 against non-GAAP LBITDA of $1,788,000 a year ago. Non-GAAP adjusted EBITDA was $20,560,000 against $12,425,000 a year ago.

For the nine months, the company reported net sales of $598,043,000 against $527,387,000 a year ago. Operating loss was $11,682,000 against $36,900,000 a year ago. Loss from continuing operations before income taxes was $147,574,000 against $99,287,000 a year ago. Net loss from continuing operations was $146,357,000 or $1.35 per basic and diluted against $91,789,000 or $0.88 per basic and diluted a year ago. Net loss was $135,737,000 or $1.25 per basic and diluted share against $231,731,000 or $2.22 per basic and diluted share a year ago. Non-GAAP net loss from continuing operations, as adjusted was $33,365,000 against $54,692,000 a year ago. Adjusted non-GAAP loss was $14,334,000 against $33,118,000 a year ago. Adjusted non-GAAP loss per share was $0.13 against $0.32 a year ago. Non-GAAP LBITDA was $25,314,000 against EBITDA of $19,923,000 a year ago. Non-GAAP adjusted EBITDA was $72,858,000 against $50,414,000 a year ago.

The company raised its full-year 2018 net sales guidance, excluding the impact of the Cartiva acquisition, to approximately $825 million to $828 million, from its previous guidance of approximately $812 million to $822 million.  This guidance range assumes foreign currency exchange rates for the remainder of the year that are generally in line with current rates.  In addition, this range implies full-year 2018 constant currency net sales growth of 11% to 12%, excluding the estimated $9 million impact of the four fewer selling days in fourth quarter of 2018.  Additionally, the company is providing guidance on the impact of the Cartiva acquisition. The company is raising its full-year 2018 non-GAAP adjusted EBITDA from continuing operations guidance to a range of $110 million to $116 million from its previous range of $106 million to $113 million.  Cartiva is estimated to be roughly neutral to 2018 non-GAAP adjusted EBITDA on an as reported basis. The company expects its non-GAAP adjusted earnings per share from continuing operations, including share-based compensation for full-year 2018 to be a loss of $0.08 to $0.03 per diluted share.